

ASX ANNOUNCEMENT

15th March 2022

RESPIRI ANNOUNCES FIRST REIMBURSED REMOTE PATIENT MONITORING (RPM) PILOT PROGRAM IN THE US: CHILDREN'S HOSPITAL OF MICHIGAN

Respiri Limited (ASX:RSH) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory health management is pleased to announce its first RPM pilot program involving wheezo® with the Children's Hospital of Michigan. The program was secured with our RPM partner Access Telehealth and will provide the full RPM solution, including patient engagement for a select group of children living with asthma (similar to the Remote Asthma Monitoring Program (RAMP) developed in Australia). Wheezo® and the Access patient engagement services qualify for reimbursement through Medicaid and also selected private health insurers. The program will be piloted with the view of including wheezo® as a standard in RPM for relevant children with asthma in an effort to reduce exacerbations and hospitalisations, improving patient outcomes and reducing healthcare costs.

The wheezo® devices will be supplied and paid for by Access Telehealth with Medicaid reimbursing the monthly data fees (Software as a Service, SaaS). **Medicaid** in the United States is a federal and state program that helps with healthcare costs for some people with limited income and resources. Medicaid also offers benefits not normally covered by Medicare, including nursing home care and personal care services. The main difference between the two programs is that Medicaid covers healthcare costs for people with low incomes while Medicare provides health coverage for the elderly. The Health Insurance Association of America describes Medicaid as "a government insurance program for persons of all ages whose income and resources are insufficient to pay for health care. This pilot program design is the business model that Respiri will pursue within the broader private health insurer US market. Private insurers take their reimbursement leads from the Centres of Medicare and Medicaid Services (CMS) reimbursement.

With over 225 beds and extensive asthma outpatient services, Children's Hospital of Michigan, an affiliate of Central Michigan University, is one of the largest children's hospitals in the USA. Located in Detroit City with a population of more than 3.5M people, almost 0.9M people under the age of 18 and approximately 70,000 children living with asthma. The institution is a premier healthcare service provider for the children in the city.

CEO and Managing Director of Respiri, Mr Marjan Mikel said "We are very excited about this important RPM collaboration with the Children's Hospital and Access Telehealth as it demonstrates that there is a strong acceptance of wheezo® as part of asthma management. Furthermore, our recent participation at the American Academy of Allergy, Asthma and Immunology (AAAAI) meeting in Phoenix, continues to corroborate the need for innovative technologies, such as wheezo®, in RPM. Respiri is well placed to establish its product offerings across the lucrative and CPT (Current Procedural Terminology) reimbursable US market."

Associate Professor Pavadee Poowuttikul, Division Chief of Allergy/Immunology and Rheumatology, is the lead in this initiative for the hospital and said "We have been searching for new technologies that allow us to better monitor the management of our difficult-to-control, inner-city asthma patients once they leave our hospital and care. Many times, our patients and their families come to us without recognizing that they are actively wheezing or do not remember how often they have been wheezing in the last few months. Wheezo provides us with an easy and real time solution that should give us greater transparency around patient management from the real world where asthma problems occur. We are excited about this collaboration".

The response wheezo® received at the American Academy of Allergy, Asthma and Immunology (AAAAI) meeting in Phoenix in February from Key Opinion Leaders and Physicians was positive and the Respi/Access Telehealth teams received over 40 qualified leads from major hospitals and a publicly listed Telehealth provider with discussions already underway for wheezo® RPM CPT reimbursement services

In addition, Mr Mikel went on to say “this partnership continues to demonstrate that we are executing on our USA strategy as planned and our progress is well ahead of where we had planned to be at this stage of our commercialisation journey.”

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respi Limited
P: +61 408 462 873
E: marjan@respi.co

Mr Nicholas Smedley
Executive Chairman
Respi Limited
P: +61 447 074 160
E: nicholas@respi.co

This ASX announcement dated 15th March 2022 has been authorised for release by the Board of Directors of Respi Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respi Limited.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.